PTC Inc. logo PTC - PTC Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 20
HOLD 10
SELL 3
STRONG
SELL 0
| PRICE TARGET: $162.71 DETAILS
HIGH: $198.00
LOW: $130.00
MEDIAN: $164.00
CONSENSUS: $162.71
UPSIDE: 7.27%

Stock News

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28.

Aug 24, 2026 04:00 AM • prnewswire.com
PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT's lead asset, has driven rapid revenue growth, accounting for 63% of product revenue and expanding across major global markets. ST-920, acquired from Sangamo, is a late-stage gene therapy for Fabry Disease; FDA approval could significantly enhance PTCT's valuation.

Aug 24, 2026 01:31 AM • seekingalpha.com
PTC Advances Leadership in AI-Driven Design with Launch of Onshape FeatureScript MCP Server

PTC Advances Leadership in AI-Driven Design with Launch of Onshape FeatureScript MCP Server

Enables engineers to create reusable custom CAD features using natural language and AI, no programming experience required Automates feature development through AI-assisted building, testing, debugging, and refinement   Captures engineering knowledge as reusable CAD automation that can be shared across teams without ongoing AI interactions or recurring costs BOSTON, Aug. 13, 2026 /PRNewswire/ -- PTC  (NASDAQ: PTC) today announced the availability of the new FeatureScript™ MCP Server capability in its Onshape® CAD and PDM platform. Available through its Onshape Labs™ initiative, the capability enables engineers to create custom CAD features using natural language and AI.

Aug 13, 2026 04:30 AM • prnewswire.com
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J.

Aug 12, 2026 12:01 PM • prnewswire.com
PTC Strengthens ALM Portfolio with New AI and Configuration Management Capabilities for Enterprise Complexity

PTC Strengthens ALM Portfolio with New AI and Configuration Management Capabilities for Enterprise Complexity

Launches Codebeamer 3.3, Codebeamer AI 1.2, and Pure Variants 7.3, strengthening traceability, change management, and AI governance Automates how engineering teams carry approved changes across product variants and controls who can approve them Introduces an AI Search Assistant powered by semantic search, helping teams quickly find more complete and accurate results BOSTON, Aug. 5, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the latest enhancements to its application lifecycle management (ALM) portfolio with the release of its Codebeamer®  3.3, Codebeamer AI 1.2, and Pure Variants™ 7.3 solutions. Together, the releases address two challenges engineering teams face regularly: keeping changes consistent across product variants and finding the right information within them.

Aug 05, 2026 04:30 AM • prnewswire.com
PTC Will Participate in Upcoming Investor Conferences

PTC Will Participate in Upcoming Investor Conferences

BOSTON, Aug. 5, 2026 /PRNewswire/ -- PTC (Nasdaq: PTC) today announced that it will participate in the following conferences.  What:  Oppenheimer 29th Annual Technology, Internet & Communications Virtual Conference       When:  1x1's on Wednesday, August 12, 2026  What:  Citi's 2026 Global TMT Conference       When:  Wednesday, September 9, 2026  What:  Berenberg European Conference       When:  1x1's on Tuesday, December 1, 2026 What:  Barclays 24th Annual Global Technology Conference When:  Wednesday, December 9, 2026 View conference schedule HERE.

Aug 05, 2026 03:00 AM • prnewswire.com
PTC Launches Arena Connect to Simplify Enterprise Integrations for Manufacturers

PTC Launches Arena Connect to Simplify Enterprise Integrations for Manufacturers

Simplifies how teams integrate systems, automate workflows, and manage information across the product ecosystem Helps accelerate workflow creation with pre-built templates, a library of low-code connectors, and an intuitive visual interface Introduces AI-powered product change summaries, automated BOM compliance checks, and enhanced Onshape-Arena connection features as part of the broader 2026.2 release BOSTON, Aug. 4, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the release of the Arena Connect™ capability within its Arena®  product lifecycle management (PLM) and quality management system (QMS) 2026.2 release. Arena Connect helps manufacturers connect business applications, other Arena workspaces, and automated workflows across the product value chain, making it easier to move information between the systems teams rely on every day.

Aug 04, 2026 04:30 AM • prnewswire.com
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026 revenue of $151 million, with continued broad uptake and geographical expansion – – Strong cash position of $2.2 billion as of June 30, 2026 – WARREN, N.J., July 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2026.

Jul 30, 2026 12:01 PM • prnewswire.com

Price Targets